focus -WSS

focus

author：leisure time 2025-08-12 06:43:04 - browse：787

Illustration of a crowd of people looking toward a cityscape. — Adobe

Few public health challenges have been more daunting and persistent than the opioid crisis, which started because of egregious conduct by opioid manufacturers and now is driven by an influx of fentanyl. In my home state of New Hampshire — which has been at the forefront of this heartbreaking epidemic for more than a decade — too many promising futures have been snatched away. As we look to the next stage of bipartisan efforts to take on this challenge, we must quickly reauthorize and expand the SUPPORT Act, which expired Sept. 30. It laid a new foundation for our response to this epidemic — and now it can be used to increase access to the gold standard of treatment for addiction.

In 2018, we came together across party lines to pass the SUPPORT Act, which established vital infrastructure for communities in New Hampshire and across the country to treat addiction, help people recover, and prevent substance misuse in the first place.

While there are dozens of vital measures in this legislation, one of the most critical provisions helped expand access to medication-assisted treatment, the gold standard of addiction care. Access to this lifesaving medication, buprenorphine, has historically been limited by law and clinician reluctance, fueled by harmful stigmas surrounding addiction treatment.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

focus

WSS

Analysis of pharma R&D ranks Novo Nordisk, J&J above their peers

When prostate cancer spreads, where it goes matters

Leukemia patients are helped by Syndax's new type of therapy

Radiology is caught between AI's potential and concern for patients

With measles on the rise, a personal story of a devastating disease

Data integrity in scientific journals requires "effort" by publishers, institutions

explore

focus

entertainment

Supreme Court strikes down use of affirmative action

Supreme Court wrestles with OxyContin maker's bankruptcy deal

Heart attack and stroke risk calculators need revising

Big Tobacco's 'harm reduction': Is it for real, or a sham?

Continuity nursing helped my family in our darkest PICU moments

Bird flu: Don't repeat Covid's 'health versus the economy' framing

State Dept. review finds Biden bears some blame for Afghanistan failures

Readers respond to H5N1 and livestock movements, and more

As demand for Covid shots wanes, Moderna seeks its next success

Why sickle cell disease is getting the first CRISPR treatment

entertainment

Leukemia patients are helped by Syndax's new type of therapy

Pfizer plans to depart BIO

Second House panel advances two

Military medical care influenced by rank and race, new study finds

Cytokinetics CEO stresses company can launch heart drug on its own

STAT Event – Decoding Clinical Trials: Venture Capitalists Talk Early Biotech R&D

focus

explore

focus

knowledge